Cargando…

A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer

Background: Capecitabine plus oxaliplatin (XELOX) is considered one of the primary chemotherapy regimens for patients with metastatic colorectal cancer (CRC). Oxaliplatin plus S-1 (OS) has also demonstrated significant efficacy in CRC. We performed this randomized phase II study to evaluate the effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jung Han, Zang, Dae Young, Chung, Ik-Joo, Cho, Sang-Hee, Park, Keon Uk, Oh, Ho-Suck, Lee, Kyung Hee, Lee, Bong Hwa, Kim, Min-Jeong, Park, Choong Kee, Han, Boram, Kim, Hyeong Su, Choi, Dae Ro, Song, Hun Ho, Jung, Joo Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565854/ https://www.ncbi.nlm.nih.gov/pubmed/26366218 http://dx.doi.org/10.7150/jca.12819

Ejemplares similares

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
por: Kim, Seung Tae, et al.
Publicado: (2014)

Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer
por: Yoo, Changhoon, et al.
Publicado: (2018)

A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients
por: Jang, Geundoo, et al.
Publicado: (2013)

Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction
por: Hwang, Seung Jae, et al.
Publicado: (2006)

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
por: Kim, Seung Tae, et al.
Publicado: (2016)

Capecitabine Plus Oxaliplatin Combination Therapy for Basal Cell Carcinoma
por: Rhee, Jiyoung, et al.
Publicado: (2019)

The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients
por: Jung, Joo Young, et al.
Publicado: (2014)

Oxaliplatin-induced Pulmonary Fibrosis: Two Case Reports
por: Ryu, Chun-Geun, et al.
Publicado: (2011)

Factors Influencing Clinicians' Choice of Adjuvant S-1 versus Capecitabine plus Oxaliplatin after Curative Gastrectomy in Patients with Gastric Cancer
por: Lee, Ha Yeon, et al.
Publicado: (2016)

Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage
por: Shin, Kabsoo, et al.
Publicado: (2019)

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
por: Aitini, Enrico, et al.
Publicado: (2012)

A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation
por: Lee, Guk Jin, et al.
Publicado: (2023)

Genipin increases oxaliplatin-induced cell death through autophagy in gastric cancer
por: Kim, Bo Ram, et al.
Publicado: (2020)

Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial
por: Kim, Seung Tae, et al.
Publicado: (2019)

Syringaresinol Alleviates Oxaliplatin-Induced Neuropathic Pain Symptoms by Inhibiting the Inflammatory Responses of Spinal Microglia
por: Lee, Ji Hwan, et al.
Publicado: (2022)

Long-Term Survival Outcomes of Elderly Patients Treated With S-1 or Capecitabine Plus Oxaliplatin for Stage II or III Gastric Cancer: A Multicenter Cohort Study
por: Choi, Seohee, et al.
Publicado: (2022)

Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer
por: Kim, Han Jo, et al.
Publicado: (2011)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Clinicopathologic Significance of VHL Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review
por: Kim, Hyeong Su, et al.
Publicado: (2018)

Pathological and Prognostic Impacts of FGFR2 Overexpression in Gastric Cancer: A Meta-Analysis
por: Kim, Hyeong Su, et al.
Publicado: (2019)

Role of AMPK in Regulation of Oxaliplatin-Resistant Human Colorectal Cancer
por: Park, Sun Young, et al.
Publicado: (2022)

Sarcoidosis Associated with Oxaliplatin-Based Chemotherapy for Colorectal Cancer
por: Choi, Ji Hoon, et al.
Publicado: (2014)

A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy
por: Kim, Su-Hyun, et al.
Publicado: (2018)

Cannabidiol Overcomes Oxaliplatin Resistance by Enhancing NOS3- and SOD2-Induced Autophagy in Human Colorectal Cancer Cells
por: Jeong, Soyeon, et al.
Publicado: (2019)

A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma
por: Lee, Dae-Won, et al.
Publicado: (2018)

SILAC-Based Quantitative Proteomic Analysis of Oxaliplatin-Resistant Pancreatic Cancer Cells
por: Kim, Young Eun, et al.
Publicado: (2021)

Analgesic Effect of Melittin on Oxaliplatin-Induced Peripheral Neuropathy in Rats
por: Choi, Seunghwan, et al.
Publicado: (2019)

A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
por: Han, Boram, et al.
Publicado: (2021)

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer
por: Kang, Yoon-Koo, et al.
Publicado: (2021)

Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Study
por: Lee, Chang Min, et al.
Publicado: (2020)

A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
por: Lee, Dae-Won, et al.
Publicado: (2023)

Oxaliplatin-Induced Chronic Peripheral Neurotoxicity: A Prospective Analysis in Patients with Colorectal Cancer
por: Baek, Kyung Kee, et al.
Publicado: (2010)

Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors
por: Ferrarotto, Renata, et al.
Publicado: (2013)

Docosahexaenoic Acid Enhances Oxaliplatin-Induced Autophagic Cell Death via the ER Stress/Sesn2 Pathway in Colorectal Cancer
por: Jeong, Soyeon, et al.
Publicado: (2019)

Effect of green tea extracts on oxaliplatin-induced peripheral neuropathy in rats
por: Lee, Jung Soo, et al.
Publicado: (2012)

Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer
por: Kim, Yeon-Joo, et al.
Publicado: (2013)

A Case of Liver Fibrosis with Splenomegaly after Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer
por: Kang, Gu Hyum, et al.
Publicado: (2013)

Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer
por: Yang, Xiao-Hui, et al.
Publicado: (2020)

Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report
por: Woo, Hyun Sun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_c4ccdkf7dc5s3e2q94b54urbdo